Cargando…

Disruption of the sialic acid/Siglec-9 axis improves antibody-mediated neutrophil cytotoxicity towards tumor cells

Upregulation of surface expressed sialoglycans on tumor cells is one of the mechanisms which promote tumor growth and progression. Specifically, the interactions of sialic acids with sialic acid-binding immunoglobulin-like lectins (Siglecs) on lymphoid or myeloid cells transmit inhibitory signals an...

Descripción completa

Detalles Bibliográficos
Autores principales: Lustig, Marta, Chan, Chilam, Jansen, J. H. Marco, Bräutigam, Maria, Kölling, Max A., Gehlert, Carina Lynn, Baumann, Niklas, Mester, Simone, Foss, Stian, Andersen, Jan Terje, Bastian, Lorenz, Sondermann, Peter, Peipp, Matthias, Burger, Renate, Leusen, Jeanette H. W., Valerius, Thomas
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10279866/
https://www.ncbi.nlm.nih.gov/pubmed/37346044
http://dx.doi.org/10.3389/fimmu.2023.1178817
_version_ 1785060680911552512
author Lustig, Marta
Chan, Chilam
Jansen, J. H. Marco
Bräutigam, Maria
Kölling, Max A.
Gehlert, Carina Lynn
Baumann, Niklas
Mester, Simone
Foss, Stian
Andersen, Jan Terje
Bastian, Lorenz
Sondermann, Peter
Peipp, Matthias
Burger, Renate
Leusen, Jeanette H. W.
Valerius, Thomas
author_facet Lustig, Marta
Chan, Chilam
Jansen, J. H. Marco
Bräutigam, Maria
Kölling, Max A.
Gehlert, Carina Lynn
Baumann, Niklas
Mester, Simone
Foss, Stian
Andersen, Jan Terje
Bastian, Lorenz
Sondermann, Peter
Peipp, Matthias
Burger, Renate
Leusen, Jeanette H. W.
Valerius, Thomas
author_sort Lustig, Marta
collection PubMed
description Upregulation of surface expressed sialoglycans on tumor cells is one of the mechanisms which promote tumor growth and progression. Specifically, the interactions of sialic acids with sialic acid-binding immunoglobulin-like lectins (Siglecs) on lymphoid or myeloid cells transmit inhibitory signals and lead to suppression of anti-tumor responses. Here, we show that neutrophils express among others Siglec-9, and that EGFR and HER2 positive breast tumor cells express ligands for Siglec-9. Treatment of tumor cells with neuraminidases or a sialyl transferase inhibitor significantly reduced binding of a soluble recombinant Siglec-9-Fc fusion protein, while EGFR and HER2 expression remained unchanged. Importantly, the cytotoxic activity of neutrophils driven by therapeutic EGFR or HER2 antibodies in vitro was increased by blocking the sialic acid/Siglec interaction, either by reducing tumor cell sialylation or by a Siglec-9 blocking antibody containing an effector silenced Fc domain. In vivo a short-term xenograft mouse model confirmed the improved therapeutic efficacy of EGFR antibodies against sialic acid depleted, by a sialyltransferase inhibitor, tumor cells compared to untreated cells. Our studies demonstrate that sialic acid/Siglec interactions between tumor cells and myeloid cells can impair antibody dependent tumor cell killing, and that Siglec-9 on polymorphonuclear cells (PMN) is critically involved. Considering that PMN are often a highly abundant cell population in the tumor microenvironment, Siglec-9 constitutes a promising target for myeloid checkpoint blockade to improve antibody-based tumor immunotherapy.
format Online
Article
Text
id pubmed-10279866
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-102798662023-06-21 Disruption of the sialic acid/Siglec-9 axis improves antibody-mediated neutrophil cytotoxicity towards tumor cells Lustig, Marta Chan, Chilam Jansen, J. H. Marco Bräutigam, Maria Kölling, Max A. Gehlert, Carina Lynn Baumann, Niklas Mester, Simone Foss, Stian Andersen, Jan Terje Bastian, Lorenz Sondermann, Peter Peipp, Matthias Burger, Renate Leusen, Jeanette H. W. Valerius, Thomas Front Immunol Immunology Upregulation of surface expressed sialoglycans on tumor cells is one of the mechanisms which promote tumor growth and progression. Specifically, the interactions of sialic acids with sialic acid-binding immunoglobulin-like lectins (Siglecs) on lymphoid or myeloid cells transmit inhibitory signals and lead to suppression of anti-tumor responses. Here, we show that neutrophils express among others Siglec-9, and that EGFR and HER2 positive breast tumor cells express ligands for Siglec-9. Treatment of tumor cells with neuraminidases or a sialyl transferase inhibitor significantly reduced binding of a soluble recombinant Siglec-9-Fc fusion protein, while EGFR and HER2 expression remained unchanged. Importantly, the cytotoxic activity of neutrophils driven by therapeutic EGFR or HER2 antibodies in vitro was increased by blocking the sialic acid/Siglec interaction, either by reducing tumor cell sialylation or by a Siglec-9 blocking antibody containing an effector silenced Fc domain. In vivo a short-term xenograft mouse model confirmed the improved therapeutic efficacy of EGFR antibodies against sialic acid depleted, by a sialyltransferase inhibitor, tumor cells compared to untreated cells. Our studies demonstrate that sialic acid/Siglec interactions between tumor cells and myeloid cells can impair antibody dependent tumor cell killing, and that Siglec-9 on polymorphonuclear cells (PMN) is critically involved. Considering that PMN are often a highly abundant cell population in the tumor microenvironment, Siglec-9 constitutes a promising target for myeloid checkpoint blockade to improve antibody-based tumor immunotherapy. Frontiers Media S.A. 2023-06-06 /pmc/articles/PMC10279866/ /pubmed/37346044 http://dx.doi.org/10.3389/fimmu.2023.1178817 Text en Copyright © 2023 Lustig, Chan, Jansen, Bräutigam, Kölling, Gehlert, Baumann, Mester, Foss, Andersen, Bastian, Sondermann, Peipp, Burger, Leusen and Valerius https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Immunology
Lustig, Marta
Chan, Chilam
Jansen, J. H. Marco
Bräutigam, Maria
Kölling, Max A.
Gehlert, Carina Lynn
Baumann, Niklas
Mester, Simone
Foss, Stian
Andersen, Jan Terje
Bastian, Lorenz
Sondermann, Peter
Peipp, Matthias
Burger, Renate
Leusen, Jeanette H. W.
Valerius, Thomas
Disruption of the sialic acid/Siglec-9 axis improves antibody-mediated neutrophil cytotoxicity towards tumor cells
title Disruption of the sialic acid/Siglec-9 axis improves antibody-mediated neutrophil cytotoxicity towards tumor cells
title_full Disruption of the sialic acid/Siglec-9 axis improves antibody-mediated neutrophil cytotoxicity towards tumor cells
title_fullStr Disruption of the sialic acid/Siglec-9 axis improves antibody-mediated neutrophil cytotoxicity towards tumor cells
title_full_unstemmed Disruption of the sialic acid/Siglec-9 axis improves antibody-mediated neutrophil cytotoxicity towards tumor cells
title_short Disruption of the sialic acid/Siglec-9 axis improves antibody-mediated neutrophil cytotoxicity towards tumor cells
title_sort disruption of the sialic acid/siglec-9 axis improves antibody-mediated neutrophil cytotoxicity towards tumor cells
topic Immunology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10279866/
https://www.ncbi.nlm.nih.gov/pubmed/37346044
http://dx.doi.org/10.3389/fimmu.2023.1178817
work_keys_str_mv AT lustigmarta disruptionofthesialicacidsiglec9axisimprovesantibodymediatedneutrophilcytotoxicitytowardstumorcells
AT chanchilam disruptionofthesialicacidsiglec9axisimprovesantibodymediatedneutrophilcytotoxicitytowardstumorcells
AT jansenjhmarco disruptionofthesialicacidsiglec9axisimprovesantibodymediatedneutrophilcytotoxicitytowardstumorcells
AT brautigammaria disruptionofthesialicacidsiglec9axisimprovesantibodymediatedneutrophilcytotoxicitytowardstumorcells
AT kollingmaxa disruptionofthesialicacidsiglec9axisimprovesantibodymediatedneutrophilcytotoxicitytowardstumorcells
AT gehlertcarinalynn disruptionofthesialicacidsiglec9axisimprovesantibodymediatedneutrophilcytotoxicitytowardstumorcells
AT baumannniklas disruptionofthesialicacidsiglec9axisimprovesantibodymediatedneutrophilcytotoxicitytowardstumorcells
AT mestersimone disruptionofthesialicacidsiglec9axisimprovesantibodymediatedneutrophilcytotoxicitytowardstumorcells
AT fossstian disruptionofthesialicacidsiglec9axisimprovesantibodymediatedneutrophilcytotoxicitytowardstumorcells
AT andersenjanterje disruptionofthesialicacidsiglec9axisimprovesantibodymediatedneutrophilcytotoxicitytowardstumorcells
AT bastianlorenz disruptionofthesialicacidsiglec9axisimprovesantibodymediatedneutrophilcytotoxicitytowardstumorcells
AT sondermannpeter disruptionofthesialicacidsiglec9axisimprovesantibodymediatedneutrophilcytotoxicitytowardstumorcells
AT peippmatthias disruptionofthesialicacidsiglec9axisimprovesantibodymediatedneutrophilcytotoxicitytowardstumorcells
AT burgerrenate disruptionofthesialicacidsiglec9axisimprovesantibodymediatedneutrophilcytotoxicitytowardstumorcells
AT leusenjeanettehw disruptionofthesialicacidsiglec9axisimprovesantibodymediatedneutrophilcytotoxicitytowardstumorcells
AT valeriusthomas disruptionofthesialicacidsiglec9axisimprovesantibodymediatedneutrophilcytotoxicitytowardstumorcells